Last reviewed · How we verify

NCT06700915

A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and Metabolism

Recruiting now NA Last updated 13 December 2024
What this trial tests

NA trial testing Diaberine in Metabolism Disorder in 80 participants. Currently enrolling.

Timeline
3 October 2024
Primary endpoint
1 May 2025
1 May 2025

Quick facts

Lead sponsorUltimate International, Inc.
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment80
Start date3 October 2024
Primary completion1 May 2025
Estimated completion1 May 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ultimate International, Inc.

Who can join

Adults 18 to 70, any sex, with Metabolism Disorder or Nutraceutical. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, triple-blind, placebo-controlled study will evaluate the efficacy of Diaberine, a berberine-based nutraceutical, in aiding blood sugar regulation and metabolism in 80 participants over 24 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metabolism Disorder

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06700915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing